Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Barr Pharmaceuticals has completed its acquisition of Shire's ADHD drug Adderall for $63 million, after no objections were raised by the Federal Trade Commission.
Subscribe to our email newsletter
The Hart-Scott-Rodino waiting period for the Barr’s acquisition of Shire’s Adderall expired without further action from the US Federal Trade Commission. As a result, the product acquisition agreement that Duramed Pharmaceuticals, a subsidiary of Barr, and Shire entered into can be finalized.
Under the terms of the agreement, Duramed will pay $63 million to purchase Shire’s Adderall tablets. The company will re-launch the product in December 2006.
Aderall is used as part of a total treatment program in children with behavioral disorders.